RxDoctor Payments DataLook up a doctor →

John Campbell, MD

Addiction Medicine · Kentwood, MINPI 1417901232

Payments from drug & device makers

$8,460in general payments, 2019–2025

Across 510 payments — averaging $16.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$981
  • Pfizer$948
  • AbbVie$853
  • Novo Nordisk$682
  • Vanda Pharmaceuticals Inc.$498
  • GSK$350
  • plus $4K from 44 others

What the payments were for

  • Food & beverage$8,421100%
  • Education$390%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,460 in reported general payments places this provider in the 90th percentile of 62 addiction medicine providers in Michigan.

See all addiction medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$236,325
Medicare patients
165
Services billed
2,549

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol16$19,581
TrulicityDulaglutide14$18,610
EliquisApixaban23$18,287
JardianceEmpagliflozin12$16,243
XareltoRivaroxaban18$13,180
Atorvastatin Calcium165$2,828
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl30$2,714
Levothyroxine Sodium112$1,897
Metoprolol Succinate59$1,459
Losartan Potassium100$1,444
Rosuvastatin Calcium51$1,430
LantusInsulin Glargine,hum.Rec.Anlog15$1,374
Mirtazapine28$1,281
Hydrocortisone23$1,153
Potassium Chloride19$1,142

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$981$19,58116 claims
Lilly USA, LLCTrulicity$153$18,61014 claims
PfizerEliquis$948$18,28723 claims
Boehringer IngelheimJardiance$185$16,24312 claims
Johnson & JohnsonXarelto$190$13,18018 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 62 addiction medicine providers in Michigan.

Other addiction medicine in Kentwood

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →